Начало・Списък с акции・Innoviva Inc

Innoviva Inc

Затворен

СекторЗдравеопазване

21.16 2.42

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.51

Максимум

20.94

Ключови измерители
By Trading Economics
Приходи	-270M -83M
Продажби	22M 120M
P/E Средно за сектора	4.754 57.002
EPS	0.59
Марж на печалбата	-69.754
Служители	159
EBITDA	28M 267M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+95.43% upside

Дивиденти
By Acuity
Следващи печалби	3.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-39M 1.5B
Предишно отваряне	18.74
Предишно затваряне	21.16

Настроения в новините

By Acuity

24%

76%

67 / 340 Класиране в Healthcare

Innoviva Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.08.2026 г., 19:41 ч. UTC

Innoviva Inc shares are lower during Thursday's session, with no specific news identified. The stock remains below its 20-day moving average.

12.08.2026 г., 19:06 ч. UTC

Event

Innoviva Inc's therapies are finalists for the 2026 Prix Galien USA Award, but shares are trading lower, remaining below Tuesday's close.

11.08.2026 г., 19:16 ч. UTC

Innoviva Inc's shares are higher in Tuesday's session, reflecting a modest gain since Monday's close. The stock remains below its 20-day moving average.

10.08.2026 г., 19:16 ч. UTC

News

Innoviva shares are higher despite mixed analyst ratings and a price target cut from Cantor Fitzgerald to $34.00. HC Wainwright maintains a $46.00 target.

7.08.2026 г., 21:01 ч. UTC

Innoviva Inc shares are lower in after-market hours, reflecting a decline since Friday's close and trading near the lower end of their one-month range.

6.08.2026 г., 19:51 ч. UTC

News

Innoviva Inc shares are higher as the company shifts to a diversified healthcare model, supported by $773 million in investments and positive momentum since Wednesday.

5.08.2026 г., 21:01 ч. UTC

Innoviva Inc shares are trading higher in after-market hours, recovering from a session low. No specific news was identified to explain the movement.

3.08.2026 г., 19:46 ч. UTC

News

Innoviva Inc shares are lower today, continuing a downward trend. Analysts from BTIG and HC Wainwright maintain buy ratings with targets of $42.00 and $46.00.

31.07.2026 г., 20:06 ч. UTC

Shares of Innoviva Inc. are trading lower, continuing a downward trend. The stock remains below its 20-day moving average amid no specific news.

30.07.2026 г., 19:02 ч. UTC

Innoviva Inc shares are declining amid market weakness and rising jobless claims. The stock remains near the lower end of its one-month range.

29.07.2026 г., 19:06 ч. UTC

Macro Event

Innoviva Inc shares are lower today as market scrutiny increases following the Federal Reserve's decision to maintain interest rates amid ongoing geopolitical tensions.

28.07.2026 г., 20:03 ч. UTC

Innoviva Inc shares are higher today, continuing an upward trend since Monday. No specific news was identified to explain the price movement.

27.07.2026 г., 19:56 ч. UTC

Innoviva Inc shares are lower today, reflecting broader market trends amid a significant drop in oil prices. No specific company news was identified.

21.07.2026 г., 15:46 ч. UTC

Innoviva Inc shares are higher today, reflecting a broader trend in rising equity indices. The stock remains below its 20-day moving average.

20.07.2026 г., 18:31 ч. UTC

Innoviva Inc shares are lower today, reflecting broader weakness in the Pharmaceuticals sub-sector. The stock has reversed from a recent trend of higher closes.

Сравнение с други в отрасъла

Ценова промяна

Innoviva Inc Прогноза

Ценова цел

By TipRanks

95.43% нагоре

12-месечна прогноза

Среден 40.67 USD 95.43%

Висок 46 USD

Нисък 34 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Innoviva Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Innoviva Inc през последните 3 месеца.

Настроение

By Acuity

67 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.